APGE

NEUTRALM&A

Apogee Therapeutics, Inc.

2026-09-02

Price

$135.07

-0.01%

This is the 2026-09-02 snapshot — the signals and analysis for APGE as of this single trading day.

View full APGE research hub →

Score10.5Priority

Signals6/8 DNA1/13 Act · 2/4 Risk

SentimentNEUTRALScore: 8

Volume0.0xvs 20d avg

Analysis

Apogee Therapeutics (APGE) is trading as a pure merger arbitrage play following AbbVie's definitive agreement to acquire the company for $135.11 per share in cash. The exceptionally low 1.4% realized volatility and technical signals like QUIET_STORM and PERFECT_STACK reflect the mechanical pinning of the stock to its acquisition price rather than organic price discovery. The current RISK_ON macro regime, characterized by pristine credit internals and ultra-tight high-yield spreads, perfectly supports this dynamic by ensuring AbbVie faces zero financing friction to close the $10.9 billion deal in Q3 2026.

Fired Signals

ALPHA MALEQUIET STORMSTEADY CLIMBGOLDEN CROSSMARKET LEADERPERFECT STACKBARGAIN HUNTERWEAK FINISHCHURNING

Key Takeaways

APGE is trading at $135.07, leaving a microscopic 4-cent arbitrage spread against AbbVie's $135.11 all-cash buyout offer [1.2.6].
The 3.7x volume spike indicates urgent final institutional positioning or merger arbitrage clearing ahead of the imminent Q3 2026 deal close.
With financing risk eliminated via AbbVie's massively oversubscribed $10 billion bond offering, the primary remaining risk is an unexpected regulatory block.

← Back to 2026-09-02 View Full APGE History →Yahoo Finance &nearr;